Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib [0.03%]
brigatinib在克唑替尼耐药或不耐受的转移性ALK阳性非小细胞肺癌患者中的潜力
Rohit K Jain,Hongbin Chen
Rohit K Jain
In the last decade, there have been major therapeutic advances in the management of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. Crizotinib was the first approved ALK inhibitor with significant benefit...
Brian Ko,Daniel Paucar,Balazs Halmos
Brian Ko
Non-small-cell lung cancers that harbor activating mutations in the EGFR gene represent an important molecularly defined subset of lung cancer. Despite dramatic initial responses with first- and second-generation EGFR-directed tyrosine-kina...
Prognostic value of soluble major histocompatibility complex class I polypeptide-related sequence A in non-small-cell lung cancer - significance and development [0.03%]
可溶型MHC-I类多肽相关序列A在非小细胞肺癌预后价值的意义及发展研究
Roberto Cascone,Annalisa Carlucci,Matteo Pierdiluca et al.
Roberto Cascone et al.
Soluble major histocompatibility complex class I polypeptide-related sequence A (sMICA) is a useful marker in surveillance of lung cancer. High serum sMICA level in patients with non-small-cell lung cancer (NSCLC) seems to be a poor prognos...
Hideyuki Harada,Shigeyuki Murayama
Hideyuki Harada
This review summarizes the past and present status of proton beam therapy (PBT) for lung cancer. PBT has a unique characteristic called the Bragg peak that enables a reduction in the dose of normal tissue around the tumor, but is sensitive ...
Maria Bonomi,Costantino De Filippis,Egesta Lopci et al.
Maria Bonomi et al.
Malignant pleural mesothelioma (MPM) is a disease with limited therapeutic options, the management of which is still controversial. Diagnosis is usually made by thoracoscopy, which allows multiple biopsies with histological subtyping and is...
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy [0.03%]
奥希替尼治疗非小细胞肺癌：设计、研发及临床定位
Mariacarmela Santarpia,Alessia Liguori,Niki Karachaliou et al.
Mariacarmela Santarpia et al.
The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase inhibitors (TKIs) marked the advent of the era of precision medicine fo...
Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challenges [0.03%]
慢性阻塞性肺疾病在肺癌患者中的患病率、影响及管理挑战
Dionisios Spyratos,Eleni Papadaki,Sofia Lampaki et al.
Dionisios Spyratos et al.
Chronic obstructive pulmonary disease (COPD) and lung cancer share a common etiological factor (cigarette smoking) and usually coexist in everyday clinical practice. The prevalence of COPD among newly diagnosed patients with lung cancer som...
New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer [0.03%]
非小细胞肺癌患者的预后生物标志物及贝伐单抗的治疗效果
Maiko Niki,Takashi Yokoi,Takayasu Kurata et al.
Maiko Niki et al.
Background: Several biomarkers have emerged as potential prognostic and predictive markers for non-small-cell lung cancer (NSCLC). Successful inhibition of angiogenesis with the antivascular endothelial growth factor anti...
Psychosocial challenges for patients with advanced lung cancer: interventions to improve well-being [0.03%]
晚期肺癌患者的心理社会挑战：改善患者生存质量的干预措施
Rebecca H Lehto
Rebecca H Lehto
As compared to other cancers, lung malignancies are associated with high symptom burden, poorer prognosis, and stigmatization. Such factors increase psychological distress and negatively impact quality of life. Research has documented the e...
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab [0.03%]
非小细胞肺癌的新PD-L1抑制剂-阿特朱单抗的影响
Nagashree Seetharamu,Isabel R Preeshagul,Kevin M Sullivan
Nagashree Seetharamu
The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other...